All News

Nouf Al hemmadi Tweet
NoufAhmedAlham2
PMR classification criteria by ⁦@anisha_dua⁩ ⁦@RheumNow⁩ #RNL2023 Bursal and biceps tenosynovitis gets one point in PMR classification criteria. https://t.co/Lj1X9mkgBz
Dr. Rachel Tate Tweet
uptoTate
Check out MothertoBaby fact sheets by the NIH and LactRX (by mother to baby) app for pregnancy, disease, and medications. Dr. C. Chambers highlighted this today at #RNL2023 @RheumNow
Nouf Al hemmadi Tweet
NoufAhmedAlham2
PMR lab studies by ⁦@anisha_dua⁩ ⁦@RheumNow⁩ #RNL2023 Majority of patients will have elevated inflammatory markers. Rapid clinical response to low dose of steroid. https://t.co/AgdIJ5YbOu
Nouf Al hemmadi Tweet
NoufAhmedAlham2
Some points to consider in relapsing PMR , by ⁦@anisha_dua⁩ ⁦@RheumNow⁩ #RNL2023 Elevated ESR and CRP rule out GCA. Relapses are common with steroid tapering, especially below 5mg. https://t.co/D17mdly7z5
Eric Dein Tweet
ericdeinmd
Great #RNL2023 Plenary with "Miracle Larry" after 128 days in hospital for COVID-19, on 3-year anniversary of going into coma "I am the expert on what this virus can do. I don't want the world to ever forget" @RheumNow https://t.co/kTuDXDhTtQ
Robert B Chao, MD Tweet
doctorRBC
Tremendously emotional (and unfiltered) first person account of his fight with COVID-19 by Miracle Larry who thanked our Dr. Cush @RheumNow for his ingenuity in fighting COVID-19, thanking healthcare workers for all they do, and reminding us to be empathic. #RNL2023 https://t.co/i0D7r8dR8n
Robert B Chao, MD Tweet
doctorRBC
Dr. Carol Langford on GPA treatment Duration of remission maintenance therapy? - at least 2 years, after 2 years, maintenance appropriate in many cases - consider RTX, and other cDMARDs (MTX, MMF, AZA) @RheumNow #RNL2023 https://t.co/VmswcnzN5v
Eric Dein Tweet
ericdeinmd
#RNL2023 Rob Spiera: I often use aspirin a day, especially if cranial complications and no contra-indications" No prospective studies, 2 large retrospective studies suggesting benefit @RheumNow https://t.co/OedVG03yN3
Janet Pope Tweet
Janetbirdope
#RNL2023 Resources for pregnancy and lactation for patients on various #medications and #chronic #diseases. Have a look. Pregnant 🫃 #baby and #breast #feeding. https://t.co/A8zmBUAylG
Dr. Rachel Tate Tweet
uptoTate
I use US in my practice and since this data was presented last year, I’ve been evaluating subacromial/deltoid bursas my PMR patients. ⁦@anisha_dua⁩ reviews imaging at #RNL2023 ⁦@RheumNow⁩ https://t.co/1TYdXNmcx0
Eric Dein Tweet
ericdeinmd
Conaghan: "Most promising study in OA" at #RNL2023 NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated? Can there be sustained response. Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪 @RheumNow https://t.co/eBMEPBG9wn
Eric Dein Tweet
ericdeinmd
Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA @RheumNow https://t.co/Ieagp8mq31
Eric Dein Tweet
ericdeinmd
Dr Philip Conaghan at #RNL2023 X-rays are misleading in OA OA is a CLINICAL disease Radiographs do not help in diagnosis or monitoring ⁦@RheumNow⁩ https://t.co/ZrAfPN02qi
Eric Dein Tweet
ericdeinmd
@RheumNow Live 2023 Starts Tomorrow! Or does it start earlier? Love that there is a pre-learn and pre-test to set the stage for #RNL2023 Excited for this talk by @anisha_dua on assessment for GCA/PMR #RheumTwitter https://t.co/VcawlnaPFf
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×